Literature DB >> 14745054

Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial.

R A J Esselink1, R M A de Bie, R J de Haan, M W P M Lenders, P C G Nijssen, M J Staal, H M M Smeding, P R Schuurman, D A Bosch, J D Speelman.   

Abstract

OBJECTIVE: To compare the efficacy of unilateral pallidotomy and bilateral subthalamic nucleus (STN) stimulation in patients with advanced Parkinson disease (PD) in a randomized, observer-blind, multicenter trial.
METHODS: Thirty-four patients with advanced PD were randomly assigned to have unilateral pallidotomy or bilateral STN stimulation. The primary outcome was the change from baseline to 6 months in the motor part of the Unified PD Rating Scale (motor UPDRS) in the off phase. Secondary outcomes were parkinsonian symptoms in the on phase (motor UPDRS), dyskinesias (Clinical Dyskinesia Rating Scale and dyskinesias UPDRS), functional status (activities of daily living UPDRS and Schwab and England scale), PD Quality of Life questionnaire, changes in drug treatment, and adverse effects.
RESULTS: The off phase motor UPDRS score improved from 46.5 to 37 points in the group of pallidotomy patients and from 51.5 to 26.5 in the STN stimulation patients (p = 0.002). Of the secondary outcome measures, on phase motor UPDRS and dyskinesias UPDRS improved significantly in favor of the STN stimulation patients. Reduction of antiparkinsonian drugs was greater after STN stimulation than after pallidotomy. One patient in each group had a major adverse effect.
CONCLUSIONS: Bilateral STN stimulation is more effective than unilateral pallidotomy in reducing parkinsonian symptoms in patients with advanced PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745054     DOI: 10.1212/01.wnl.0000103235.12621.c3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  41 in total

1.  Health-related quality of life as an outcome variable in Parkinson's disease.

Authors:  Pablo Martinez-Martin; Mónica M Kurtis
Journal:  Ther Adv Neurol Disord       Date:  2012-03       Impact factor: 6.570

2.  Deep brain stimulation in Parkinson's disease.

Authors:  S J Groiss; L Wojtecki; M Südmeyer; A Schnitzler
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

3.  Clinical heterogeneity in newly diagnosed Parkinson's disease.

Authors:  Bart Post; Johannes D Speelman; Rob J de Haan
Journal:  J Neurol       Date:  2008-03-17       Impact factor: 4.849

Review 4.  Parkinson's disease.

Authors:  Carl E Clarke; A Peter Moore
Journal:  BMJ Clin Evid       Date:  2007-08-01

Review 5.  Deep brain stimulation for Parkinson's disease.

Authors:  Patricia Limousin; Irene Martinez-Torres
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

6.  Movement-related discharge in the macaque globus pallidus during high-frequency stimulation of the subthalamic nucleus.

Authors:  Andrew J Zimnik; Gerald J Nora; Michel Desmurget; Robert S Turner
Journal:  J Neurosci       Date:  2015-03-04       Impact factor: 6.167

Review 7.  Current Practice and the Future of Deep Brain Stimulation Therapy in Parkinson's Disease.

Authors:  Leonardo Almeida; Wissam Deeb; Chauncey Spears; Enrico Opri; Rene Molina; Daniel Martinez-Ramirez; Aysegul Gunduz; Christopher W Hess; Michael S Okun
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 8.  The effect of deep brain stimulation on quality of life in movement disorders.

Authors:  A Diamond; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

9.  A comprehensive model of health-related quality of life in Parkinson's disease.

Authors:  M Visser; S M van Rooden; D Verbaan; J Marinus; A M Stiggelbout; J J van Hilten
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

10.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.